Suicide Gene Therapy

Successful VDEPT for Cancer Uses E. coli Nitroreductase and CB1954

Published in Gene Therapy Weekly, September 28th, 1998

The efficacy of virus-directed enzyme prodrug therapy (VDEPT) using retrovirally delivered Escherichia coli nitroreductase (NTR) and CB1954 was demonstrated for the first time in vivo using a human pancreatic cancer xenograft model.

Most enzyme/prodrug systems are based on herpes simplex virus type 1 thymidine kinase and the antiviral drug ganciclovir or cytosine deaminase and the prodrug 5-fluorocytosine. These suicide gene therapy combinations work as antimetabolites, whose toxicity is dependent upon ongoing DNA replication. As such, growth-arrested cells are not significantly altered by these therapies and their application to some cancers is limited.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-09-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry